Clinical Remission and Reduction of Circulating Nephritic Factors by Combining Rituximab With Belimumab in a Case of Complement Factor 3 Glomerulopathy
Saved in:
| Main Authors: | Mieke van Schaik, Aiko P.J. de Vries, Frederike J. Bemelman, Ton J. Rabelink, Leendert A. Trouw, Cees van Kooten, Yoe Kie Onno Teng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | Kidney International Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S246802492401492X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report
by: Tineke Kraaij, et al.
Published: (2025-02-01) -
Defining Nephritic Factors as Diverse Drivers of Systemic Complement Dysregulation in C3 Glomerulopathy
by: Jill J. Hauer, et al.
Published: (2024-02-01) -
Clinical features and risk factors of primary peritonitis in children with primary nephritic syndrome
by: DING Juan-juan, et al.
Published: (2016-01-01) -
Obinutuzumab in Rituximab-Intolerant Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Patients
by: Jolijn R. van Leeuwen, et al.
Published: (2025-04-01) -
WCN25-1407 INCIDENCE, RISK FACTORS AND OUTCOME OF TRANSPLANT GLOMERULOPATHY
by: EBY MATHEW, et al.
Published: (2025-02-01)